BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) VP Lynne Powell sold 5,280 shares of the business’s stock in a transaction on Thursday, November 8th. The stock was sold at an average price of $8.15, for a total value of $43,032.00. Following the transaction, the vice president now directly owns 8,905 shares of the company’s stock, valued at approximately $72,575.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Lynne Powell also recently made the following trade(s):

  • On Monday, November 5th, Lynne Powell sold 100 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total value of $800.00.
  • On Thursday, November 1st, Lynne Powell sold 1,544 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $7.51, for a total value of $11,595.44.
  • On Friday, October 19th, Lynne Powell sold 100 shares of BioCryst Pharmaceuticals stock. The stock was sold at an average price of $7.50, for a total value of $750.00.

BCRX stock traded down $0.39 during midday trading on Friday, reaching $7.70. 512,158 shares of the stock were exchanged, compared to its average volume of 449,626. The firm has a market capitalization of $875.66 million, a P/E ratio of -9.87 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.25 and a 52 week high of $8.31. The company has a quick ratio of 1.25, a current ratio of 1.25 and a debt-to-equity ratio of 0.35.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.03). The firm had revenue of $1.45 million for the quarter, compared to the consensus estimate of $2.53 million. BioCryst Pharmaceuticals had a negative return on equity of 145.89% and a negative net margin of 428.00%. As a group, equities research analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.96 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of BCRX. Wells Fargo & Company MN grew its position in BioCryst Pharmaceuticals by 29.3% during the 1st quarter. Wells Fargo & Company MN now owns 68,052 shares of the biotechnology company’s stock worth $324,000 after acquiring an additional 15,403 shares during the last quarter. Northern Trust Corp grew its position in shares of BioCryst Pharmaceuticals by 1.1% in the 1st quarter. Northern Trust Corp now owns 1,188,876 shares of the biotechnology company’s stock valued at $5,671,000 after buying an additional 13,044 shares during the last quarter. UBS Group AG grew its position in shares of BioCryst Pharmaceuticals by 190.7% in the 1st quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock valued at $1,390,000 after buying an additional 191,157 shares during the last quarter. Allianz Asset Management GmbH grew its position in shares of BioCryst Pharmaceuticals by 40.5% in the 1st quarter. Allianz Asset Management GmbH now owns 231,761 shares of the biotechnology company’s stock valued at $1,105,000 after buying an additional 66,783 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its position in shares of BioCryst Pharmaceuticals by 79.1% in the 2nd quarter. State of Wisconsin Investment Board now owns 100,300 shares of the biotechnology company’s stock valued at $575,000 after buying an additional 44,300 shares during the last quarter. Institutional investors and hedge funds own 79.82% of the company’s stock.

A number of equities analysts have recently commented on the company. BidaskClub cut BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. ValuEngine upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Royal Bank of Canada restated a “buy” rating and set a $9.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $8.50 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. Finally, JMP Securities boosted their price objective on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $9.89.

ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals, Inc. (BCRX) VP Lynne Powell Sells 5,280 Shares of Stock” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dailypolitical.com/2018/11/10/biocryst-pharmaceuticals-inc-bcrx-vp-lynne-powell-sells-5280-shares-of-stock.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: Bond

Insider Buying and Selling by Quarter for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.